Nath Bio-Genes (India) Limited (BOM:537291)
India · Delayed Price · Currency is INR 145.85
-5.15 (-3.41%)
At close: Dec 4, 2025
Nath Bio-Genes (India) Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Operating Revenue | 4,164 | 3,649 | 3,326 | 3,014 | 2,784 | 3,076 | Upgrade |
Other Revenue | 1.31 | 1.31 | 1.41 | - | - | -0 | Upgrade |
| 4,165 | 3,650 | 3,328 | 3,014 | 2,784 | 3,076 | Upgrade | |
Revenue Growth (YoY) | 18.67% | 9.70% | 10.42% | 8.26% | -9.49% | 9.89% | Upgrade |
Cost of Revenue | 1,118 | 902.49 | 903.04 | 814.33 | 936.65 | 980.14 | Upgrade |
Gross Profit | 3,047 | 2,748 | 2,425 | 2,199 | 1,847 | 2,095 | Upgrade |
Selling, General & Admin | 749.85 | 522.24 | 442.11 | 372.48 | 382.11 | 410.98 | Upgrade |
Other Operating Expenses | 1,757 | 1,716 | 1,482 | 1,338 | 1,088 | 1,013 | Upgrade |
Operating Expenses | 2,548 | 2,276 | 1,957 | 1,741 | 1,501 | 1,452 | Upgrade |
Operating Income | 498.75 | 471.49 | 467.6 | 458.79 | 345.7 | 643.36 | Upgrade |
Interest Expense | -115.34 | -99 | -86.29 | -95.73 | -101.25 | -79.02 | Upgrade |
Interest & Investment Income | 35.89 | 35.89 | 3.23 | 0.18 | 10.93 | 12.14 | Upgrade |
Currency Exchange Gain (Loss) | 6.4 | 6.4 | -0.14 | 4.3 | 0.59 | -1.23 | Upgrade |
Other Non Operating Income (Expenses) | 30.54 | -4.39 | -3.26 | -5.93 | -3.88 | -8.45 | Upgrade |
EBT Excluding Unusual Items | 456.24 | 410.38 | 381.15 | 361.59 | 252.08 | 566.79 | Upgrade |
Gain (Loss) on Sale of Assets | -10.35 | -10.35 | 0.01 | -0.01 | 0.04 | 0.04 | Upgrade |
Other Unusual Items | 26.04 | 5.4 | 34.49 | - | -887.82 | - | Upgrade |
Pretax Income | 472.34 | 405.84 | 415.65 | 361.64 | -634.34 | 567.51 | Upgrade |
Income Tax Expense | 30.68 | 19.85 | 19.46 | 11.53 | 39.52 | 10.9 | Upgrade |
Net Income | 441.66 | 386 | 396.19 | 350.11 | -673.85 | 556.62 | Upgrade |
Net Income to Common | 441.66 | 386 | 396.19 | 350.11 | -673.85 | 556.62 | Upgrade |
Net Income Growth | 12.17% | -2.57% | 13.16% | - | - | 10.26% | Upgrade |
Shares Outstanding (Basic) | 19 | 19 | 19 | 19 | 19 | 19 | Upgrade |
Shares Outstanding (Diluted) | 19 | 19 | 19 | 19 | 19 | 19 | Upgrade |
Shares Change (YoY) | -0.51% | - | - | - | - | - | Upgrade |
EPS (Basic) | 23.27 | 20.31 | 20.85 | 18.42 | -35.46 | 29.29 | Upgrade |
EPS (Diluted) | 23.27 | 20.31 | 20.85 | 18.42 | -35.46 | 29.29 | Upgrade |
EPS Growth | 12.75% | -2.57% | 13.16% | - | - | 10.26% | Upgrade |
Free Cash Flow | -131.7 | 96.61 | 478.18 | 354.85 | -39.56 | -104.34 | Upgrade |
Free Cash Flow Per Share | -6.94 | 5.08 | 25.16 | 18.67 | -2.08 | -5.49 | Upgrade |
Dividend Per Share | 2.000 | 2.000 | 2.000 | 2.000 | 2.000 | 2.000 | Upgrade |
Gross Margin | 73.16% | 75.28% | 72.86% | 72.98% | 66.35% | 68.13% | Upgrade |
Operating Margin | 11.97% | 12.92% | 14.05% | 15.22% | 12.42% | 20.92% | Upgrade |
Profit Margin | 10.60% | 10.57% | 11.91% | 11.62% | -24.21% | 18.10% | Upgrade |
Free Cash Flow Margin | -3.16% | 2.65% | 14.37% | 11.77% | -1.42% | -3.39% | Upgrade |
EBITDA | 539.71 | 509.32 | 500.21 | 488.91 | 376.54 | 671.52 | Upgrade |
EBITDA Margin | 12.96% | 13.95% | 15.03% | 16.22% | 13.53% | 21.83% | Upgrade |
D&A For EBITDA | 40.95 | 37.83 | 32.61 | 30.12 | 30.84 | 28.16 | Upgrade |
EBIT | 498.75 | 471.49 | 467.6 | 458.79 | 345.7 | 643.36 | Upgrade |
EBIT Margin | 11.97% | 12.92% | 14.05% | 15.22% | 12.42% | 20.92% | Upgrade |
Effective Tax Rate | 6.49% | 4.89% | 4.68% | 3.19% | - | 1.92% | Upgrade |
Revenue as Reported | 4,209 | 3,695 | 3,333 | 3,019 | 2,802 | 3,092 | Upgrade |
Advertising Expenses | - | 48.31 | 50.51 | 37.04 | 16.34 | 19.43 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.